

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: RavenQuest Biomed Inc.(the “**Issuer**”).

Trading Symbol: RQB

Number of Outstanding Listed Securities: 93,335,552

Date: Month of March 2018

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**In March 2018, the Issuer completed the acquisition of 8649081 Canada Inc. (“Bloomera”), a Markham Ontario based licensed producer of cannabis under the Access to Cannabis for Medical Purpose Regulation.**

**Please refer to “Schedule B” for further details.**

**Concurrently, the Issuer signed a Memorandum of Understanding with Fort McMurray #468 First Nation ("FM 468") to collaborate in the development, operation and financing of a purpose-built facility for the production of cannabis on lands controlled by FM 468.**

**Please refer to "Schedule D" for further details.**

**Concurrently, the Issuer has commenced trading on the OTCQB market in the United States and Frankfurt Stock Exchange, under the symbol "RVVQF" and "1IT" respectively.**

**Please refer to "Schedule E and F" for further details.**

**Concurrently, the Issuer acquired the remaining 64,000 shares from AGB's non-controlling interest in exchange for the issuance of 9,152 common shares. AGB is now a wholly-owned subsidiary of the Issuer.**

2. Provide a general overview and discussion of the activities of management.

**Please refer to Item #1 for further details.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Please refer to Item #1 above for further details.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None**

8. Describe the acquisition of new customers or loss of customers.

**None**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**None**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None**

14. Provide details of any securities issued and options or warrants granted.

**In March 2018, the Issuer completed the first tranche of a brokered private placement of units and convertible debenture units of the Issuer, with Haywood Securities Inc. ("Haywood") acting as lead agent. In connection with completion of the brokered placement, the Issuer issued 3,581,300 units at a price of \$1.25 per unit, and 15,000 debenture units at a price of \$1,000 per debenture unit, for aggregate gross proceeds to the Company of \$19,476,625. The Company also completed a concurrent non-brokered private placement of 4,052,000 units, for additional gross proceeds to the Issuer of \$5,065,000. The aggregate gross proceeds to the Company was \$24,541,625.**

**Each unit consists of one common share of the Issuer, and one common share purchase warrant. Each warrant is exercisable to acquire an additional common share of the Issuer at a price of \$1.50 per a period of 24 months, subject to acceleration in the event that the closing price of the Company's common shares on the Canadian Securities Exchange is greater than \$2.75 for a period of ten consecutive trading days.**

**Each debenture unit consists of an unsecured convertible debenture of the Issuer in the principal amount of \$1,000 and 690 warrants. The debentures are convertible at the option of the holder into common shares at a price of \$1.45 per share, bear an interest rate of ten percent per annum and mature 24 months after the date of issue.**

In connection with the brokered placement, the Issuer paid a commission of \$1,558,130, of which \$932,953 was issued in 746,362 units at a deemed price per unit of \$1.25 and \$625,117 was paid in cash, and issued to the agent 1,178,090 compensation options. Each compensation option entitles the holder to acquire a common share of the Company at a price per common share of \$1.25 for a period of 24 months from the closing of the offering. As additional compensation, the Issuer paid to the agent a corporate finance fee equal to \$80,000 in the form of 64,000 units (valued at \$80,000) and issued to the agent 64,000 corporate finance compensation options, having the same terms and attributes as the compensation options.

Please refer to “Schedule A” for further details.

In March 2018, the Issuer completed an additional tranche of its brokered private placement of units and convertible debenture units of the Issuer, with Haywood Securities Inc. acting as lead agent. In connection with completion of this tranche of the brokered placement, the Issuer issued 1,440,000 units at a price of \$1.25 per unit for gross proceeds of \$1,800,000.

Each unit consists of one common share of the Issuer, and one common share purchase warrant. Each warrant is exercisable to acquire an additional common share of the Issuer at a price of \$1.50 per share for a period of 24 months, subject to acceleration in the event that the closing price of the Issuer's common shares on the Canadian Securities Exchange is greater than \$2.75 for a period of ten consecutive trading days.

In connection with this tranche of the brokered placement, the Issuer paid a commission of \$144,000, which was satisfied through the issuance of 115,200 units and 115,200 compensation options. Each compensation option entitles the holder to acquire a common share of the Issuer at a price per common share of \$1.25 for a period of 24 months from the date of issuance.

Please refer to “Schedule C” for further details.

In March 2018, the Issuer completed an additional tranche of its non-brokered private placement of units of the Issuer. In connection with the completion of this tranche of the non-brokered placement, the Issuer issued an additional 84,000 units at a price of \$1.25 per unit for gross proceeds of \$105,000.

Each unit consists of one common share of the Issuer, and one common share purchase warrant. Each warrant is exercisable to acquire an additional common share of the Issuer at a price of \$1.50 per share for a period of 24 months, subject to acceleration in the event that the closing price of the Issuer's common shares on the Canadian Securities Exchange is greater than \$2.75 for a period of ten consecutive trading days.

In connection with this tranche of the non-brokered placement, the Issuer paid a commission of \$84,000, which was satisfied through the issuance of 6,720 units and 6,720 compensation options. Each compensation option entitles the holder to acquire a common share of the Issuer at a price per common share of \$1.25 for a period of 24 months from the date of issuance.

Please refer to “Schedule G” for further details.

15. Provide details of any loans to or by Related Persons.

**None**

16. Provide details of any changes in directors, officers or committee members.

**None**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**The Licensed Cannabis Industry exists in a developing regulatory environment. Upon completion of the proposed transactions the Issuer will be subject to the evolving legislation and regulations, specifically, the *Access to Cannabis for Medical Purposes Regulations* ("ACMPR"). The *Marihuana for Medical Purposes Regulations* ("MMPR"), the predecessor to the ACMPR, was declared invalid by the Federal Court of Canada on February 24, 2016 and the ACMPR was enacted on August 24, 2016, in order to replace the MMPR. There is no guarantee that the ACMPR will not be repealed or replaced in the future.**

## *“Schedule A”*



NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS

### **RAVENQUEST COMPLETES FINANCINGS FOR \$24.5 MILLION**

**NR18-04**

**March 2, 2018**

**FOR IMMEDIATE RELEASE...Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB)** has completed the first tranche of its previously-announced brokered private placement (the “**Brokered Placement**”) of units (each, a “**Unit**”) and convertible debenture units (each, a “**Debenture Unit**”) of the Company, with Haywood Securities Inc. (“**Haywood**”) acting as lead agent. In connection with completion of the Brokered Placement, the Company issued 3,581,300 Units at a price of \$1.25 per Unit, and 15,000 Debenture Units at a price of \$1,000 per Debenture Unit, for aggregate gross proceeds to the Company of \$19,476,625. The Company also completed a concurrent non-brokered private placement (the “**Non -Brokered Placement**” and, together with the Brokered Placement, the “**Offering**”) of 4,052,000 Units, for additional gross proceeds to the Company of \$5,065,000. The aggregate gross proceeds to the Company from the Offering was \$24,541,625.

“The closing of this financing represents an integral step toward closing the acquisition of RavenQuest's first licensed facility” stated George Robinson, Chief Executive Officer of the Company. “We are thrilled to see that both segments of the offering were oversubscribed, demonstrating the high-level of confidence that the market has in our company's unique combination of innovation, strategic vision and execution. RavenQuest is appreciative of this confidence and fully intends to surpass expectations as we continue our growth strategy throughout 2018 and beyond.” Robinson continued by stating “in addition, the oversubscription of this financing funds the construction of Alberta Green Biotech, our Edmonton facility which is scheduled for completion in mid-2018. At this point, all of our 11,000-kilogram production capacity is fully funded.”

Each “**Unit**” consists of one common share of the Company, and one common share purchase warrant (each, a “**Warrant**”). Each Warrant is exercisable to acquire an additional common share of the Company at a price of \$1.50 per a period of twenty -four months, subject to acceleration in the event that the closing price of the Company's common shares on the Canadian Securities Exchange is greater than \$2.75 for a period of ten consecutive trading days.

Each “**Debenture Unit**” consists of an unsecured convertible debenture of the Company in the principal amount of \$1,000 (each, a “**Debenture**”) and 690 Warrants. The Debentures are convertible at the option of the holder into common shares at a price of \$1.45 per share, bear an interest rate of ten percent per annum and mature twenty-four months after the date of issue.

The proceeds of the private placement will be used by the Company to finance the acquisition of 8649081 Canada Inc. ("**Bloomera**"), and for general working capital purposes. Bloomera is a licensed producer of cannabis under the Access to Cannabis for Medical Purposes Regulations based in Markham, Ontario. The acquisition of Bloomera is expected to close shortly.

In connection with the Brokered Placement, the Company paid a commission of \$1,558,130, of which \$932,952.50 was issued in Units at a deemed price per Unit of \$1.25 and \$625,117.50 was paid in cash, and issued to the Agent 1,178,090 compensation options (each, a "**Compensation Option**"). Each Compensation Option entitles the holder to acquire a common share of the Company at a price per common share of \$1.25 for a period of twenty-four months from the closing of the Offering. As additional compensation, the Company paid to the Agent a corporate finance fee equal to \$80,000 in the form of Units at a deemed issue price of \$1.25 per Unit and issued to the Agent 64,000 corporate finance compensation options, having the same terms and attributes as the Compensation Options.

All securities issued in connection with the Offering are subject to a statutory four-month-and-one-day hold period, in accordance with applicable securities legislation.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

#### **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

***RAVENQUEST BIOMED INC.***

*"George Robinson"*  
*Chief Executive Officer*

*For further information, please contact:*  
*Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

#### ***Cautionary Note Regarding Forward-Looking Statements***

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or*

*conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*



## ***“Schedule B”***



### **RAVENQUEST EXPANDS NATIONAL PRESENCE; COMPLETES BLOOMERA ACQUISITION**

**NR18-05**

**March 2, 2018**

**March 1, 2018 – Vancouver, British Columbia – RavenQuest BioMed Inc. (CSE: RQB)** (the "RavenQuest") is pleased to announce that it has completed the acquisition of 8649081 Canada Inc. ("Bloomera"), a Markham, Ontario based licensed producer of cannabis under the Access to Cannabis for Medical Purposes Regulations.

Under the terms of the transaction, the Company has acquired all of the outstanding share capital of Bloomera in consideration for a cash payment of \$15,000,000, and the issuance of 10,400,000 common shares to the existing shareholders of Bloomera.

Bloomera currently holds a Health Canada License to Cultivate and will initially add approximately 2,000 kilograms of annual production of cannabis to RavenQuest's investment division. RavenQuest also owns Alberta Green Biotech, an Edmonton facility with expected annual production of approximately 7000 kilograms which will be ready for cultivation in mid-summer 2018. Given RavenQuest's growing methodology and application of yield-maximization research being developed in partnership with McGill University, RavenQuest expects to produce at least 11,000 kilograms of cannabis annually from these two facilities.

"Closing this transaction marks a significant milestone for our company. With the addition of Bloomera, we are delighted to now have direct access to the Greater Toronto Area (GTA), Canada's largest cannabis market. From a diversification perspective, this addition perfectly complements our western Canadian exposure in Alberta. When you look at our presence in Ontario and Alberta, two of the nation's most dynamic cannabis markets, we feel this is a powerful combination of market exposure as we continue to build a national and ultimately global cannabis company. We will add to our portfolio on a selective basis where we see strategic benefit" stated George Robinson, CEO of RavenQuest. "The Bloomera acquisition accelerates our growth trajectory by at least six months as we begin to incorporate our revolutionary grow methodologies into production. This means we have presence with funded capacity in key provincial markets, nicely timed to coincide with the Cannabis Act becoming law of the land in Canada." he continued. "Strategically Bloomera is a tremendous fit with RavenQuest,"

#### **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

**RAVENQUEST BIOMED INC.**

*"George Robinson"*  
*Chief Executive Officer*

*For further information, please contact:*  
*Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

*Cautionary Note Regarding Forward-Looking Statements*

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*

## ***“Schedule C”***



NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS

### **RAVENQUEST COMPLETES FINAL TRANCHE OF FINANCING**

**NR18-06**

**March 13, 2018**

**FOR IMMEDIATE RELEASE...Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB)** has completed the final tranche of its previously-announced brokered private placement (the “**Brokered Placement**”) of units (each, a “**Unit**”) and convertible debenture units of the Company, with Haywood Securities Inc. acting as lead agent. In connection with completion of this final tranche of the Brokered Placement, the Company issued 1,440,000 Units at a price of \$1.25 per Unit. When combined with the earlier tranche of the Brokered Placement, and a concurrent non-brokered private placement, the aggregate gross proceeds to the Company was \$26,329,125.

RavenQuest CEO, George Robinson, stated that “the market has shown tremendous confidence in our ability to execute on our strategic vision. Both segments of this financing combined for an oversubscription of 50% from our initially stated financing amount.” Robinson further stated that “it’s exciting to look forward to eleven million grams of fully funded capacity expansion by later this year, ramping up our growth trajectory dramatically. We believe this transaction represents the beginning an exciting year for RavenQuest as we move toward federally legal adult recreational cannabis this summer.”

Each “**Unit**” consists of one common share of the Company, and one common share purchase warrant (each, a “**Warrant**”). Each Warrant is exercisable to acquire an additional common share of the Company at a price of \$1.50 per share for a period of twenty-four months, subject to acceleration in the event that the closing price of the Company's common shares on the Canadian Securities Exchange is greater than \$2.75 for a period of ten consecutive trading days.

In connection with this final tranche of the Brokered Placement, the Company paid a commission of \$144,000, which was satisfied through the issuance of 115,200 Units at a deemed price of \$1.25 per Unit, and issued 115,200 compensation options (each, a “**Compensation Option**”). Each Compensation Option entitles the holder to acquire a common share of the Company at a price per common share of \$1.25 for a period of twenty-four months from the date of issuance.

All securities issued in connection with the Brokered Private Placement are subject to a statutory four-month-and-one-day hold period, in accordance with applicable securities legislation.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities in the United States. The securities have not been and will not be registered under the United

States Securities Act of 1933, as amended (the "**U.S. Securities Act**") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

### **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

### **RAVENQUEST BIOMED INC.**

*"George Robinson"  
Chief Executive Officer*

*For further information, please contact:  
Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

### *Cautionary Note Regarding Forward-Looking Statements*

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*

## ***“Schedule D”***



### **RAVENQUEST SIGNS MOU WITH FORT McMURRAY #468 FIRST NATION**

**NR18-08**

**March 19, 2018**

**FOR IMMEDIATE RELEASE...Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, Frankfurt: IIT)** is proud to announce that it has signed a Memorandum of Understanding with Fort McMurray #468 First Nation (“FM 468”) to collaborate in the development, operation and financing of a purpose-built facility for the production of cannabis on lands controlled by FM 468.

RavenQuest has developed an indigenous-centered, end -to-end solution for cannabis production and sale on sovereign land. RavenQuest will provide its expertise to deliver the technical know-how, staff resources, and financing opportunities as they relate to the development of the Production Facility, initially sized at 24,000 square feet. In consideration, RavenQuest will receive a thirty percent (30%) ownership interest in such a facility.

The parties intend that the Production Facility will rapidly expand from its initial development to a maximum of 250,000 square feet. Under such an arrangement RavenQuest will be granted the rights to a perpetual stream of a portion of cannabis produced at the Production Facility. Any joint venture arrangement will include provisions for the continued development and expansion of the production facility.

“This MOU represents a key milestone for our organization” said George Robinson, CEO of RavenQuest. “We intend to emerge as the trusted provider of choice for Indigenous Peoples’ Cannabis industry partnerships across Canada. Our work in this area reflects a high level of understanding of the concerns and issues facing Indigenous communities across Canada. With the right partners, we see cannabis as a tremendous opportunity for economic diversification, self-reliance, employment and harm reduction within Indigenous communities. This agreement is designed to deliver on all of these fronts, providing for a mutually beneficial arrangement for FM 468 and RavenQuest moving forward.”

“By participating in the cannabis sector, it will allow Fort McMurray #468 First Nation to take one step closer to being a self-sufficient Nation for the next seven generations and providing world-class services to the Citizens” said Chief Ron Kreutzer.

#### **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

***RAVENQUEST BIOMED INC.***

*"George Robinson"  
Chief Executive Officer*

*For further information, please contact:  
Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

*Cautionary Note Regarding Forward-Looking Statements*

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*

## ***“Schedule E”***



### **RAVENQUEST OBTAINS OTCQB LISTING UNDER SYMBOL “RVVQF”**

**NR18-09**

**March 21, 2018**

**FOR IMMEDIATE RELEASE...Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT)** is pleased to announce that OTC Markets Group Inc. has advised of its qualification and has confirmed commencement of trading on the OTCQB market in the United States, with immediate effect. RavenQuest’s common shares commenced trading under the symbol “RVVQF”.

To qualify to trade on OTCQB, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, and have a professional third-party sponsor introduction.

RavenQuest CEO, George Robinson, stated that “trading on the OTCQB will allow RavenQuest to leverage our existing Canadian Securities Exchange listing as we look to expand our capital markets presence. The OTCQB provides easy access, transparency and piece of mind for U.S. investors. Established companies trade on the OTCQB and it is an honor for our company to have met the high standards required for listing”.

“The Cannabis Act federally legalizes the adult recreational use of cannabis in Canada. Having passed through the House of Commons, the bill is now in the final stages of the legislative process. Canada’s cannabis-friendly investment climate is a unique opportunity in this rapidly growing segment of the global economy, and RavenQuest is an even more unique company within the Canadian cannabis sector. Our focus upon Indigenous communities, our game-changing grow technology, our plant optimization science and our management services all allow for diversified revenue streams and tremendous growth potential. We welcome every opportunity to share our story with the world, and an OTCQB listing is a big step in that direction” Robinson continued.

RavenQuest was sponsored for OTCQB by Burns, Figa & Will, P.C., a qualified third -party firm responsible for providing guidance on OTCQB requirements and recommending membership.

RavenQuest will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “RQB”.

#### **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

***RAVENQUEST BIOMED INC.***

*"George Robinson"*  
*Chief Executive Officer*

*For further information, please contact:*  
*Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

*Cautionary Note Regarding Forward-Looking Statements*

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*



## ***“Schedule F”***



### **RAVENQUEST BEGINS TRADING ON FRANKFURT EXCHANGE UNDER SYMBOL “1IT”**

**NR18-10**

**March 21, 2018**

**FOR IMMEDIATE RELEASE...Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: 1IT) is pleased to announce that it has commenced trading on the Frankfurt Stock Exchange with immediate effect. RavenQuest’s common shares commenced trading under the symbol “1IT”.**

RavenQuest CEO, George Robinson, stated that “trading on the Frankfurt Exchange gives our capital markets exposure to a truly global reach, providing ease of access, transparency and peace of mind for European and international investors. Truly global companies have a presence in Europe and we are very excited for our company to have this listing”.

“The Cannabis Act federally legalizes the adult recreational use of cannabis in Canada. Having passed through the House of Commons, the bill is now in the final stages of the legislative process. Canada’s cannabis-friendly investment climate is a unique opportunity in this rapidly growing segment of the global economy, and RavenQuest is an even more unique company within the Canadian cannabis sector. Our focus upon Indigenous communities, our game-changing grow technology, our plant optimization science and our management services all allow for diversified revenue streams and tremendous growth potential. We welcome every opportunity to share our story with the world, and a Frankfurt listing is a big step in that direction,” Robinson continued.

RavenQuest will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “RQB” and the OTCQB under the symbol “RVVQF”.

#### **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

***RAVENQUEST BIOMED INC.***

*"George Robinson"  
Chief Executive Officer*

*For further information, please contact:  
Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

*Cautionary Note Regarding Forward-Looking Statements*

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*

## ***“Schedule G”***



NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS

### **RAVENQUEST COMPLETES FINAL TRANCHE OF NON-BROKERED FINANCING**

**NR18-11**

**March 29, 2018**

**FOR IMMEDIATE RELEASE...Vancouver, British Columbia: RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB, OTCQB: RVVQF, Frankfurt: IIT)** has completed a final tranche of its previously-announced non-brokered private placement (the “**Non-Brokered Placement**”) of units (each, a “**Unit**”). In connection with completion of this final tranche of the Non-Brokered Placement, the Company issued 84,000 Units at a price of \$1.25 per Unit. When combined with the earlier tranches of the Brokered Placement and concurrent non-brokered private placements, the aggregate gross proceeds to the Company was \$26,434,123.

Each “**Unit**” consists of one common share of the Company, and one common share purchase warrant (each, a “**Warrant**”). Each Warrant is exercisable to acquire an additional common share of the Company at a price of \$1.50 per share for a period of twenty-four months, subject to acceleration in the event that the closing price of the Company's common shares on the Canadian Securities Exchange is greater than \$2.75 for a period of ten consecutive trading days.

In connection with this final tranche of the Non-Brokered Placement, the Company paid a commission of \$ 8,400, which was satisfied through the issuance of 6,720 Units at a deemed price of \$1.25 per Unit (each a “Finder’s Unit” with the same terms and conditions as the Units. The Company also issued 6,720 broker’s warrants (the “Broker Warrants”) exercisable at a price per common share of \$1.25 for a period of twenty-four months from the date of issuance with the same terms and conditions as the Units.

All securities issued in connection with the Non- Brokered Placement are subject to a statutory four-month-and-one-day hold period, in accordance with applicable securities legislation.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

## **About RavenQuest BioMed Inc.**

Ravenquest Biomed Inc. is a diversified publicly traded cannabis company with divisions focused upon cannabis production, management services & consulting and specialized research & development.

*On Behalf of the Board of Directors of*

***RAVENQUEST BIOMED INC.***

*"George Robinson"*  
*Chief Executive Officer*

*For further information, please contact:*  
*Mathieu McDonald, Corporate Communications 604-484-1230*

*Neither Canadian Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Stock Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.*

### ***Cautionary Note Regarding Forward-Looking Statements***

*All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including statements with respect to the completion of a further tranche of the brokered private placement and the acquisition of a licensed cannabis producer. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company's public filings under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.*

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 3, 2018

Anton (Tony) Drescher  
Name of Director or Senior  
Officer

/s/ Anton (Tony) Drescher  
Signature  
Director  
Official Capacity

<b>Issuer Details</b> Name of Issuer <b>RavenQuest Biomed Inc.</b>	For Month End <b>March 2018</b>	Date of Report YY/MM/DD <b>18/04/03</b>
Issuer Address <b>#507, 837 West Hastings Street</b>		
City/Province/Postal Code <b>Vancouver, BC V6C 3N6</b>	Issuer Fax No. <b>(604) 408-7499</b>	Issuer Telephone No. <b>(604) 484-1230</b>
Contact Name <b>Anton (Tony) Drescher</b>	Contact Position <b>Director</b>	Contact Telephone No. <b>(604) 484-1230</b>
Contact Email Address <b>ajd@harbourpacific.com</b>	Web Site Address <b>www.rqbglobal.com</b>	